A Study to Evaluate the Potential Increased Risk of Seizures Among Metastatic Castration-Resistant Prostate Cancer (mCRPC) Patients Treated With Enzalutamide

This study is currently recruiting participants. (see Contacts and Locations)
Verified June 2014 by Astellas Pharma Inc
Sponsor:
Collaborator:
Medivation, Inc.
Information provided by (Responsible Party):
Astellas Pharma Inc ( Astellas Pharma Global Development, Inc. )
ClinicalTrials.gov Identifier:
NCT01977651
First received: October 31, 2013
Last updated: June 20, 2014
Last verified: June 2014
  Purpose

The objective of this study is to evaluate the incidence of seizures and monitor the safety of enzalutamide treatment in subjects with metastatic castration-resistant prostate cancer known to have risk factor(s) for seizure.


Condition Intervention Phase
Metastatic Castration- Resistant Prostate Cancer (mCRCP)
Drug: Enzalutamide
Phase 4

Study Type: Interventional
Study Design: Endpoint Classification: Safety Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: A Multicenter, Single-Arm, Open-Label, Post-Marketing Safety Study to Evaluate the Risk of Seizure Among Subjects With Metastatic Castration-Resistant Prostate Cancer (mCRPC) Treated With Enzalutamide Who Are at Potential Increased Risk of Seizure

Resource links provided by NLM:


Further study details as provided by Astellas Pharma Inc:

Primary Outcome Measures:
  • The proportion of evaluable subjects with at least one confirmed seizure as adjudicated by the Independent Adjudication Committee (IAC) [ Time Frame: 4 months ] [ Designated as safety issue: Yes ]

Estimated Enrollment: 400
Study Start Date: September 2013
Estimated Study Completion Date: June 2018
Estimated Primary Completion Date: June 2018 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: enzalutamide Drug: Enzalutamide
Oral
Other Names:
  • Xtandi,
  • MDV3100

  Eligibility

Genders Eligible for Study:   Male
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Subject has histologically confirmed metastatic adenocarcinoma of the prostate.
  • Subject has ongoing androgen deprivation therapy with a Gonadotropin-releasing hormone (GnRH) analogue (agonist or antagonist) or bilateral orchiectomy (i.e., surgical or medical castration).
  • Subject has disease progression by at least one of the following:

    1. Prostate-Specific Antigen (PSA) progression defined by a minimum of 2 rising PSA levels with an interval of at least 1 week between each draw;
    2. Bone disease progression as defined by Prostate Cancer Working Group 2 guidelines (at least 2 new lesions) on bone scan; or
    3. Soft tissue disease progression as defined by RECIST 1.1
  • For subjects who have not had an orchiectomy, there must be a plan to maintain effective GnRH-analogue therapy for the duration of the study.
  • Subject must have failed at least one course of androgen deprivation therapy (ADT), i.e., treatment with GnRH analogues.
  • Subject has an Eastern Cooperative Oncology Group (ECOG) performance status of 0-2.
  • Subject has been evaluated by a local neurologist prior to study entry who has determined the subject has at least one risk factor for seizure including:

    1. past history of seizure due to any cause except a single febrile seizure in childhood. Patients with a history of seizures should not have had a seizure within 12 months of Screening and must have had no anticonvulsants for 12 months prior to Screening,
    2. history of cerebrovascular accident (CVA) or transient ischemic attack (TIA),
    3. history of traumatic brain or head injury with loss of consciousness
    4. unexplained loss of consciousness within the last 12 months,
    5. presence of a space occupying lesion in the brain including previously treated brain metastasis(es) or primary central nervous system (CNS) tumor,
    6. history of arteriovenous malformations of the brain,
    7. history of brain infection (i.e., abscess, meningitis, or encephalitis),
    8. current use of medication that may lower seizure threshold
    9. presence of Alzheimer's disease, meningioma, leptomeningeal disease from prostate cancer.
  • Subject is able to swallow the study drug and comply with study requirements.
  • Subject agrees not to participate in another interventional study while on treatment.
  • Male subject and his female partner who is of childbearing potential must use two acceptable methods of birth control (one of which must include a condom as a barrier method of contraception) starting at Screening and continuing throughout the study period and for 3 months after final study drug administration.

    1. Two acceptable forms of birth control include:

    1. Condom (barrier method of contraception), AND
    2. One of the following acceptable forms of contraception is required:

      1. Established use of oral, injected or implanted hormonal methods of contraception.
      2. Placement of an intrauterine device (IUD) or intrauterine system (IUS).
      3. Barrier methods of contraception: Occlusive cap (diaphragm or cervical/vault caps) with spermicidal foam/gel/film/cream/suppository).
      4. Vasectomy or surgical castration at least 6 months prior to Screening.
  • Male subject must use a condom, if having sex with a pregnant woman.
  • Male subject must not donate sperm starting at Screening and throughout the study period and for at least 3 months after final drug administration.

Exclusion Criteria:

  • Subject with a history of exposure to enzalutamide.
  • Subject has severe concurrent disease, infection, or co-morbidity that, in the judgment of the Investigator, would make the subject inappropriate for enrollment.
  • Subject is currently being treated with anti-epileptics.
  • Subject has a history of seizure within the past 12 months of Screening as assessed by neurology examination and history.
  • Subject with rapidly progressing visceral disease who has not received and is thought to be able to tolerate cytotoxic chemotherapy. (However, subject who has previously received cytotoxic chemotherapy is permitted).
  • Subject has clinical signs suggestive of high or imminent risks for pathological fracture, spinal cord compression and/or cauda equina syndrome.
  • Subject's absolute neutrophil count is < 1500/microliter (µL), platelet count is < 100,000/µL) or hemoglobin is < 5.6 millimoles(mmol)/liter (L) (9 grams (g)/deciliter (dL) at Screening.
  • Subject's total bilirubin is ≥ 1.5 x upper limit of normal (ULN) (except for subjects with documented Gilbert's disease) or alanine aminotransferase (ALT) or aspartate aminotransferase (AST) is ≥ 2.5x upper limit of normal (ULN) at Screening.
  • Subject's estimated creatinine clearance (Cer) is less than 30 milliliter (mL)/minute (min) by the Cockcroft and Gault formula (Creatinine Clearance (mL/min) = (140 - age)(weight (wt) kilogram (kg) / 72 x serum creatinine (milligram (mg)/100 mL) [Cockcroft, 1976] at Screening.
  • Subject has uncontrolled hypertension as indicated by a resting systolic blood pressure > 160 millimeter of mercury (mmHg) or diastolic blood pressure > 100 millimeter of mercury (mmHg) at Screening.
  • Subject has received an investigational agent within 4 weeks or 5 half lives whichever is longer prior to Day 1.
  • Subject has shown a hypersensitivity reaction to the active pharmaceutical ingredient or any of the capsule components, including Labrasol, butylated hydroxyanisole, and butylated hydroxytoluene.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01977651

Contacts
Contact: Astellas Pharma Global Development 800-888-7704 ext 5473 clintrials.info@us.astellas.com

  Show 26 Study Locations
Sponsors and Collaborators
Astellas Pharma Global Development, Inc.
Medivation, Inc.
Investigators
Study Director: Sr. Medical Director Astellas Pharma Global Development, Inc.
  More Information

No publications provided

Responsible Party: Astellas Pharma Inc ( Astellas Pharma Global Development, Inc. )
ClinicalTrials.gov Identifier: NCT01977651     History of Changes
Other Study ID Numbers: 9785-CL-0403, 2013-003022-92, U1111-1157-0224
Study First Received: October 31, 2013
Last Updated: June 20, 2014
Health Authority: United States: Food and Drug Administration
Canada: Health Canada
France: Agence Nationale de Sécurité du Médicament et des produits de santé
Germany: Federal Institute for Drugs and Medical Devices
United Kingdom: Medicines and Healthcare Products Regulatory Agency
Spain: Agencia Española de Medicamentos y Productos Sanitarios
Belgium: Federal Agency for Medicines and Health Products, FAMHP
Sweden: Medical Products Agency
Italy: The Italian Medicines Agency
Czech Republic: State Institute for Drug Control
Australia: Department of Health and Ageing Therapeutic Goods Administration
South Korea: Korea Food and Drug Administration (KFDA)
Hong Kong: Department of Health
Singapore: Ministry of Health
New Zealand: Medsafe
Israel: Ministry of Health
Taiwan : Food and Drug Administration
Argentina: Administracion Nacional de Medicamentos, Alimentos y Tecnologia Medica
Brazil: National Health Surveillance Agency
Chile: Ministry of Health
Finland: Finnish Medicines Agency
Greece: National Organization of Medicines
Hungary: National Institute of Pharmacy

Keywords provided by Astellas Pharma Inc:
metastatic castration-resistant prostate cancer (mCRCP)
enzalutamide
seizure
Xtandi
Central Nervous System
MDV3100

Additional relevant MeSH terms:
Prostatic Neoplasms
Seizures
Genital Neoplasms, Male
Urogenital Neoplasms
Neoplasms by Site
Neoplasms
Genital Diseases, Male
Prostatic Diseases
Epilepsy
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Neurologic Manifestations
Signs and Symptoms

ClinicalTrials.gov processed this record on July 20, 2014